ReviewEuropean archives of psychiatry and clinical neuroscience2018
The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain.
Review in European archives of psychiatry and clinical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.Psychopharmacology · 2019Pooled it
- Modulating drug response through the gut microbiome: pathways to precision therapy.Archives of microbiology · 2026Review
- Suicidality as a potential risk and therapeutic target during widespread GLP-1 receptor agonists use: implications of inflammation.Frontiers in synaptic neuroscience · 2026Article
- Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.Foods (Basel, Switzerland) · 2025Review
- Are probiotics effective in reducing the metabolic side effects of psychiatric medication? A scoping review of evidence from clinical studies.Translational psychiatry · 2024Article
- Memory Reflections of the Microbiota-Gut and Oligodendrocyte Axis.CNS & neurological disorders drug targets · 2024Review
- Review
- Mechanism and treatments of antipsychotic-induced weight gain.International journal of obesity (2005) · 2023Review
- Article
- The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications.Frontiers in pharmacology · 2023Review
- [Variations in fecal microbiota of first episode schizophrenia associated with clinical assessment and serum metabolomics].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022Article
- Potential diagnostic biomarkers for schizophrenia.Medical review (2021) · 2022Review
- FI: The Fecobiome Initiative.Foodborne pathogens and disease · 2022Article
- Implications of Dietary Intake and Eating Behaviors for People with Serious Mental Illness: A Qualitative Study.Nutrients · 2022Article
- Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review.Therapeutic advances in psychopharmacology · 2022Article
- Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives.World journal of psychiatry · 2021Review
- A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia.International journal of molecular sciences · 2021Review
- Nrf2/ARE Activators Improve Memory in Aged Mice via Maintaining of Mitochondrial Quality Control of Brain and the Modulation of Gut Microbiome.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health.NPJ schizophrenia · 2021Review
- The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the emergence of knowledge implicating the human gut microbiome in the development and regulation of several physiological systems, evidence has accumulated to suggest a role for the gut microbiome in psychiatric conditions and drug response. A complex relationship between the enteric nervous system, the gut microbiota and the central nervous system has been described which allows for the microbiota to influence and respond to a variety of behaviors and psychiatric conditions. Additionally, the use of pharmaceuticals may interact with and alter the microbiota to potentially contribute to adverse effects of the drug. The gut microbiota has been described in several psychiatric disorders including depression and anxiety, but only a few reports have discussed the role of the microbiome in schizophrenia. The following review examines the evidence surrounding the gut microbiota in behavior and psychiatric illness, the role of the microbiota in schizophrenia and the potential for antipsychotics to alter the gut microbiota and promote adverse metabolic events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.